Ollin Biosciences

“Ollin Biosciences, a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, announced an oversubscribed $330 million Series B financing.”

“In a market where many rounds are quietly structured, Ollin Biosciences calling out an oversubscribed round is a deliberate signal of demand exceeding supply.”

“Ollin Biosciences...$330M Series B for antibody drugs targeting macular degeneration and diabetic macular edema”